192 related articles for article (PubMed ID: 33195647)
1. Cost-effectiveness of lutetium (
Palmer J; Leeuwenkamp OR
World J Clin Cases; 2020 Oct; 8(20):4793-4806. PubMed ID: 33195647
[TBL] [Abstract][Full Text] [Related]
2. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Lutetium [
Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
[TBL] [Abstract][Full Text] [Related]
4. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
5. Use of [
Glover M; Caplin M; Leeuwenkamp OR; Longworth L
EJC Suppl; 2021 Nov; 16():14-23. PubMed ID: 34912479
[TBL] [Abstract][Full Text] [Related]
6. [
Spada F; Campana D; Lamberti G; Laudicella R; Dellamano R; Dellamano L; Leeuwenkamp O; Baldari S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2037-2048. PubMed ID: 34950969
[TBL] [Abstract][Full Text] [Related]
7. Real-world comparison of healthcare resource utilization and costs of [
Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
9. Matching-adjusted indirect treatment comparison of [
Khan MS; Stamp E; Sammon C; Brabander T; de Herder WW; Pavel ME
EJC Suppl; 2021 Nov; 16():5-13. PubMed ID: 34912478
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
Maqsood MH; Tameez Ud Din A; Khan AH
Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265
[TBL] [Abstract][Full Text] [Related]
11. Phase 3 Trial of
Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
[TBL] [Abstract][Full Text] [Related]
12. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [
Hebert K; Santoro L; Monnier M; Castan F; Berkane I; Assénat E; Fersing C; Gélibert P; Pouget JP; Bardiès M; Kotzki PO; Deshayes E
J Nucl Med; 2024 Apr; ():. PubMed ID: 38637144
[TBL] [Abstract][Full Text] [Related]
13. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
Boucher JE; Sommers R
Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
[TBL] [Abstract][Full Text] [Related]
15. Lutetium [
Lastoria S; Rodari M; Sansovini M; Baldari S; D'Agostini A; Cervino AR; Filice A; Salgarello M; Perotti G; Nieri A; Campana D; Pellerito RE; Pomposelli E; Gaudieri V; Storto G; Grana CM; Signore A; Boni G; Dondi F; Simontacchi G; Seregni E
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38772998
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands.
Hagendijk ME; van der Schans S; Boersma C; Postma MJ; van der Pol S
Eur J Health Econ; 2021 Aug; 22(6):991-999. PubMed ID: 33829344
[TBL] [Abstract][Full Text] [Related]
17. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with
Strosberg JR; Srirajaskanthan R; El-Haddad G; Wolin EM; Chasen BR; Kulke MH; Bushnell DL; Caplin ME; Baum RP; Hendifar AE; Öberg K; Ruszniewski P; Santoro P; Broberg P; Leeuwenkamp OR; Krenning EP
J Nucl Med; 2021 Mar; 62(12):1712-8. PubMed ID: 33771903
[TBL] [Abstract][Full Text] [Related]
18. Safety and response after peptide receptor radionuclide therapy with
Kudo A; Tateishi U; Yoshimura R; Tsuchiya J; Yokoyama K; Takano S; Kobayashi N; Utsunomiya D; Hata M; Ichikawa Y; Tanabe M; Hosono M; Kinuya S
J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):487-499. PubMed ID: 34907652
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
